iProTide

Company Overview

Snapshot

Founded in January 2010, iProTide operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on drug discovery and development within the Health Tech & Life Sciences sector.

Business overview

iProTide is a Health Tech & Life Sciences company focused on enhancing protein-based drug discovery. The company's core technology involves chemical modifications within the backbone of proteins and amino acids without altering the side chain, aiming to create enhanced proteins with improved stability and distinct folding properties. Initially, iProTide plans to apply this technology to peptides and proteins associated with obesity and diabetes, serving the pharmaceutical industry by developing more efficacious, stable, and specific treatments.

Company Intelligence Q&A

What is iProTide's primary focus in drug discovery?

iProTide focuses on enhancing protein-based drug discovery through innovations related to the physical, chemical, and biological properties of amino acids, particularly for treatments related to obesity and diabetes.

What is the core technology behind iProTide's approach?

iProTide's technology is based on chemical modifications made within the backbone of proteins and amino acids, without altering the side chain, to potentially improve stability and folding properties.

Which specific therapeutic areas does iProTide target?

iProTide initially plans to focus on peptides and proteins associated with obesity and diabetes.

What is the intended benefit of iProTide's protein enhancement technology?

The technology aims to create enhanced proteins with better stability and distinct folding properties, potentially increasing activity and specificity, and enabling the re-use of peptides that previously failed clinical trials.

What is the current product development stage for iProTide?

iProTide is currently in the R&D product stage, developing its technology for protein enhancement.